India, Oct. 24 -- Cipla Ltd. has signed a deal with Eli Lilly & Co. India Pvt. Ltd. to market the blockbuster weight-loss drug Mounjaro under a new brand name-Yurpeak.

As part of the agreement, the US-based drugmaker will manufacture and supply the tirzepatide molecule to Cipla, which then will distribute and promote it as Yurpeak at the same price as Mounjaro, according to an exchange filing on Thursday (23 October 2025).

If that's the case, why partner with Cipla under a new brand name? The idea seems to be market access that India's third largest pharma maker has.

Eli Lilly's distribution network in India is limited to Tier-I cities. With Cipla, that expands to the semi-urban and rural-where diabetes and obesity is equally prevalent...